Selection and treatment of subjects having circulating myeloid cell inflammatory phenotypes

The present invention provides methods of selecting a subject for treatment with a 2-arylbenzimidazole compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof, based on the inflammatory phenotype of circulating myeloid cells. Also provided are methods for treating, slowing the progression and delaying the onset of a nervous system degenerative disease in a subject that has not been diagnosed with, but at risk of developing a nervous system degenerative disease or cognitive impairment, the methods comprising determining the onset of the nervous system degenerative disease based on the inflammatory phenotype of circulating myeloid cells, a subject is selected for treatment and administered a therapeutically effective amount of a compound of Formula I, or a salt, hydrate, deuterated analog, or fluorinated analog thereof. 本发明提供基于循环髓样细胞的炎性表型，选择用式I的2-芳基苯并咪唑化合物或其盐、水合物、氘化类似物或氟化类似物治疗的受试者的方法。还提供用于在尚未被诊断患有神经系统变性疾病但处于发展神经系统变性疾病或认知障碍的风险中的受试者中治疗神经系统变性疾病，减缓其进展和延迟其发作的方法，所述方法包括基于循环髓样细胞的炎性表型